Sparse-Sampling Bioequivalence Models Reconstructed Alprazolam and Clonazepam Curves

A modeling study tested whether limited blood samples could reproduce formulation comparisons from existing bioequivalence datasets.

What the source reports

The researchers selected five samples per volunteer from studies involving alprazolam, clonazepam, and metformin, then reconstructed concentration-time curves with a genetic-algorithm modeling approach. The modeled formulation comparisons fell within the study’s bioequivalence criteria and resembled results from the fuller datasets.

Limits of the evidence

This was a reconstruction of selected studies, not validation for every drug or sampling schedule. The authors cautioned against generalizing to highly variable pharmacokinetics or erratic metabolism. Bioequivalence compares formulations under a defined study design.

Implications for forensic review

The method should not be repurposed as a validated forensic back-calculation of an unknown ingestion. Individual dose reconstruction adds uncertainties absent from controlled formulation studies. An expert would need validation for the actual drug, sampling pattern, population, and question before applying a sparse model to a legal case.

Source and related reading

Source reviewed: The use of GA RxODE Genetics Algorithms and Running simulations from Ordinary Differential Equations (PMC8491459). This article summarizes the supplied paper; forensic applications above are interpretive analysis.

Related reading: Catatonia in Anti-NMDA Receptor Encephalitis Persisted Despite a Clonazepam-Containing Regimen; A Pill Resembling Alprazolam Is Not Proof of Alprazolam Content.